Research shows GLP-1RA drugs dramatically reduce death and cardiovascular risk in psoriasis patients

Psoriasis patients treated with glucagon-like peptide-1 receptor agonists (GLP-1RAs) face a 78% lower risk of death and a 44% lower risk of major cardiovascular events compared to those taking other diabetes or weight-loss medications, new research has shown.

This article was originally published on MedicalXpress.com

You may also be interested in:

Read More:

Lawyers Lookup